CSIMarket Company Name, Ticker, Customers, else..
 
Citius Oncology Inc  (NASDAQ: TENKU)
 

Citius Oncology Inc's Suppliers Performance

TENKU's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
TENKU Costs vs Sales of Suppliers Growth Citius Oncology Inc's cost of sales deteriorated by 0 % year on year, sequentially cost of sales grew by 49.55 % in Q3.

• More on TENKU Suppliers



Citius Oncology Inc's cost of sales deteriorated by 0 % year on year, sequentially cost of sales grew by 49.55 % in Q3.

• More on TENKU Suppliers




Citius Oncology Inc's Comment on Supply Chain


The company sources raw materials and supplies from multiple suppliers to mitigate the impact of losing any single source. The product LYMPHIR, formerly known as E7777, is developed and manufactured in compliance with federal and state regulations. The company depends on third-party manufacturers and suppliers, and any failure to meet contractual obligations with these parties could delay or halt commercialization efforts. LYMPHIR is exclusively licensed from Dr. Reddy's, who originally licensed it from Eisai. Under the license agreement, Eisai is responsible for completing clinical trials and manufacturing controls related to the Biologics License Application (BLA) production. The company has reimbursed Eisai for clinical trial expenses and is obligated to make milestone and sales-related payments. In 2025, a letter agreement amended the payment schedule for these milestone payments and outstanding invoices to Eisai.

Citius Oncology Inc's Comment on Supply Chain


The company sources raw materials and supplies from multiple suppliers to mitigate the impact of losing any single source. The product LYMPHIR, formerly known as E7777, is developed and manufactured in compliance with federal and state regulations. The company depends on third-party manufacturers and suppliers, and any failure to meet contractual obligations with these parties could delay or halt commercialization efforts. LYMPHIR is exclusively licensed from Dr. Reddy's, who originally licensed it from Eisai. Under the license agreement, Eisai is responsible for completing clinical trials and manufacturing controls related to the Biologics License Application (BLA) production. The company has reimbursed Eisai for clinical trial expenses and is obligated to make milestone and sales-related payments. In 2025, a letter agreement amended the payment schedule for these milestone payments and outstanding invoices to Eisai.







TENKU's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Citius Oncology Inc 4,747.18 0.00 -45.90 -
SUBTOTAL 0.00 0.00 0.00 -


Sources: Citius Oncology Inc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Citius Oncology Inc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.